1
|
Dhurjad P, Jaiswal P, Gupta K, Wanjari P, Sonti R. Mass spectrometry: A key tool in anti‐doping. SEPARATION SCIENCE PLUS 2022. [DOI: 10.1002/sscp.202200058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
Affiliation(s)
- Pooja Dhurjad
- Department of Pharmaceutical Analysis National Institute of Pharmaceutical Education and Research (NIPER) Hyderabad India
| | - Pooja Jaiswal
- Department of Pharmaceutical Analysis National Institute of Pharmaceutical Education and Research (NIPER) Hyderabad India
| | - Kajal Gupta
- Department of Pharmaceutical Analysis National Institute of Pharmaceutical Education and Research (NIPER) Hyderabad India
| | - Parita Wanjari
- Department of Pharmaceutical Analysis National Institute of Pharmaceutical Education and Research (NIPER) Hyderabad India
| | - Rajesh Sonti
- Department of Pharmaceutical Analysis National Institute of Pharmaceutical Education and Research (NIPER) Hyderabad India
| |
Collapse
|
2
|
A high-throughput assay for the quantification of intact Insulin-like Growth Factor I in human serum using online SPE-LC-HRMS. Clin Chim Acta 2020; 510:391-399. [DOI: 10.1016/j.cca.2020.07.054] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2020] [Revised: 07/27/2020] [Accepted: 07/27/2020] [Indexed: 02/04/2023]
|
3
|
Bronsema KJ, Klont F, Schalk FB, Bischoff R, Kema IP, van de Merbel NC. A quantitative LC-MS/MS method for insulin-like growth factor 1 in human plasma. Clin Chem Lab Med 2019; 56:1905-1912. [PMID: 29715173 DOI: 10.1515/cclm-2017-1042] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2017] [Accepted: 04/06/2018] [Indexed: 12/24/2022]
Abstract
BACKGROUND Insulin-like growth factor 1 (IGF1) is a biomarker with various applications in medicine and also in doping control. METHODS A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed that employs 15N-IGF1 as an internal standard. The method features urea-based IGF1/IGFBP-complex dissociation which is directly followed by tryptic digestion. Following solid-phase extraction (SPE) sample clean-up of the digest, IGF1 is detected by means of two signature peptides that enable quantification of total IGF1 as well as discrimination between IGF1 proteoforms with 'native' and modified or extended N-terminal sequences. RESULTS Our method is capable of measuring plasma IGF1 concentrations over the clinically relevant range of 10-1000 ng/mL and was validated according to regulatory guidelines. Comparison with the IDS-iSYS IGF1 immunoassay revealed good correlation (R2>0.97) and no proportional bias between both assays was observed after normalizing the results against the WHO reference standard for IGF1 (02/254). Evaluation of several commercially available IGF1 preparations showed varying responses which were due to inconsistencies in purity and absolute amount of IGF1 present in these products. CONCLUSIONS Our LC-MS/MS method introduces urea-based dissociation of IGF1/IGFBP-complexes to enable reliable quantification of IGF1 in plasma. Furthermore, the method is able to detect clinically relevant IGF1 levels without an enrichment procedure at the protein-level and thereby minimizes the risk of losing IGF1 proteoforms during sample preparation.
Collapse
Affiliation(s)
- Kees J Bronsema
- Bioanalytical Laboratory, PRA Health Sciences, Assen, The Netherlands
| | - Frank Klont
- Department of Analytical Biochemistry, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
| | - Frank B Schalk
- Bioanalytical Laboratory, PRA Health Sciences, Assen, The Netherlands
| | - Rainer Bischoff
- Department of Analytical Biochemistry, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
| | - Ido P Kema
- Department of Laboratory Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Nico C van de Merbel
- Bioanalytical Laboratory, PRA Health Sciences, Amerikaweg 18, 9407 TK Assen, The Netherlands.,Department of Analytical Biochemistry, Groningen Research Institute of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands, Phone: +31 592 303 431, Fax: +31 592 303 223
| |
Collapse
|
4
|
Valdés A, Lewitt M, Wiss E, Ramström M, Strage EM. Development of a Parallel Reaction Monitoring-MS Method To Quantify IGF Proteins in Dogs and a Case of Nonislet Cell Tumor Hypoglycemia. J Proteome Res 2018; 18:18-29. [PMID: 30376339 DOI: 10.1021/acs.jproteome.8b00259] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Nonislet-cell tumor hypoglycemia (NICTH) is a rare paraneoplastic phenomenon well described in dogs and humans. Tumors associated with NICTH secrete incompletely processed forms of insulin-like growth factor-II (IGF-II), commonly named big IGF-II. These forms have increased bioavailability and interact with the insulin and IGF-I receptor causing hypoglycemia and growth-promoting effects. Immunoassays designed for human samples have been used to measure canine IGF-I and -II, but they possess some limitations. In addition, there are no validated methods for measurement of big IGF-II in dogs. In the present study, a targeted parallel reaction monitoring MS-based method previously developed for cats has been optimized and applied to simultaneously quantify the serum levels of IGF-I, IGF-II, and IGFBP-3, and for the first time, the levels of big IGF-II in dogs. This method allows the absolute quantification of IGF proteins using a mixture of QPrEST proteins previously designed for humans. The method possesses good linearity and repeatability and has been used to evaluate the IGF-system in a dog with NICTH syndrome. In this dog, the levels of big IGF-II decreased by 80% and the levels of IGF-I and IGFBP-3 increased approximately 20- and 4-times, respectively, after removal of the tumor.
Collapse
Affiliation(s)
- Alberto Valdés
- Department of Chemistry-BMC, Analytical Chemistry , Uppsala University , 75123 Uppsala , Sweden
| | - Moira Lewitt
- School of Health and Life Sciences , University of the West of Scotland , PA1 2BE Paisley , United Kingdom
| | - Erica Wiss
- Albano Animal Hospital , 182 36 Stockholm , Sweden
| | - Margareta Ramström
- Department of Chemistry-BMC, Analytical Chemistry , Uppsala University , 75123 Uppsala , Sweden
| | | |
Collapse
|
5
|
Wilkin T, Baoutina A, Hamilton N. Equine performance genes and the future of doping in horseracing. Drug Test Anal 2017; 9:1456-1471. [DOI: 10.1002/dta.2198] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2016] [Revised: 03/23/2017] [Accepted: 03/24/2017] [Indexed: 01/20/2023]
Affiliation(s)
- Tessa Wilkin
- Vet Faculty; University of Sydney; Gunn Building, Sydney University, Camperdown NSW Australia
- Bioanalysis; The National Measurement Institute; 36 Bradfield Rd, Lindfield Sydney New South Wales Australia
| | - Anna Baoutina
- School of Life and Environmental Sciences, Faculty of Science; The University of Sydney; Bradfield Rd West Lindfield New South Wales Australia
| | - Natasha Hamilton
- Faculty of Veterinary Science; University of Sydney; Sydney New South Wales Australia
| |
Collapse
|
6
|
Sundberg M, Strage EM, Bergquist J, Holst BS, Ramström M. Quantitative and Selective Analysis of Feline Growth Related Proteins Using Parallel Reaction Monitoring High Resolution Mass Spectrometry. PLoS One 2016; 11:e0167138. [PMID: 27907059 PMCID: PMC5132254 DOI: 10.1371/journal.pone.0167138] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2016] [Accepted: 11/09/2016] [Indexed: 12/21/2022] Open
Abstract
Today immunoassays are widely used in veterinary medicine, but lack of species specific assays often necessitates the use of assays developed for human applications. Mass spectrometry (MS) is an attractive alternative due to high specificity and versatility, allowing for species-independent analysis. Targeted MS-based quantification methods are valuable complements to large scale shotgun analysis. A method referred to as parallel reaction monitoring (PRM), implemented on Orbitrap MS, has lately been presented as an excellent alternative to more traditional selected reaction monitoring/multiple reaction monitoring (SRM/MRM) methods. The insulin-like growth factor (IGF)-system is not well described in the cat but there are indications of important differences between cats and humans. In feline medicine IGF–I is mainly analyzed for diagnosis of growth hormone disorders but also for research, while the other proteins in the IGF-system are not routinely analyzed within clinical practice. Here, a PRM method for quantification of IGF–I, IGF–II, IGF binding protein (BP) –3 and IGFBP–5 in feline serum is presented. Selective quantification was supported by the use of a newly launched internal standard named QPrEST™. Homology searches demonstrated the possibility to use this standard of human origin for quantification of the targeted feline proteins. Excellent quantitative sensitivity at the attomol/μL (pM) level and selectivity were obtained. As the presented approach is very generic we show that high resolution mass spectrometry in combination with PRM and QPrEST™ internal standards is a versatile tool for protein quantitation across multispecies.
Collapse
Affiliation(s)
- Mårten Sundberg
- Analytical Chemistry, Department of Chemistry–BMC and Science for Life Laboratory, Uppsala University, Uppsala, Sweden
| | - Emma M. Strage
- Department of Clinical Sciences, Swedish University of Agricultural Sciences, Uppsala, Sweden
- Clinical Pathology Laboratory, University Animal Hospital, Swedish University of Agricultural Sciences, Uppsala, Sweden
| | - Jonas Bergquist
- Analytical Chemistry, Department of Chemistry–BMC and Science for Life Laboratory, Uppsala University, Uppsala, Sweden
| | - Bodil S. Holst
- Department of Clinical Sciences, Swedish University of Agricultural Sciences, Uppsala, Sweden
| | - Margareta Ramström
- Analytical Chemistry, Department of Chemistry–BMC and Science for Life Laboratory, Uppsala University, Uppsala, Sweden
- * E-mail:
| |
Collapse
|
7
|
van den Broek I, Blokland M, Nessen MA, Sterk S. Current trends in mass spectrometry of peptides and proteins: Application to veterinary and sports-doping control. MASS SPECTROMETRY REVIEWS 2015; 34:571-594. [PMID: 24375671 DOI: 10.1002/mas.21419] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/05/2013] [Revised: 11/12/2013] [Accepted: 11/12/2013] [Indexed: 06/03/2023]
Abstract
Detection of misuse of peptides and proteins as growth promoters is a major issue for sport and food regulatory agencies. The limitations of current analytical detection strategies for this class of compounds, in combination with their efficacy in growth-promoting effects, make peptide and protein drugs highly susceptible to abuse by either athletes or farmers who seek for products to illicitly enhance muscle growth. Mass spectrometry (MS) for qualitative analysis of peptides and proteins is well-established, particularly due to tremendous efforts in the proteomics community. Similarly, due to advancements in targeted proteomic strategies and the rapid growth of protein-based biopharmaceuticals, MS for quantitative analysis of peptides and proteins is becoming more widely accepted. These continuous advances in MS instrumentation and MS-based methodologies offer enormous opportunities for detection and confirmation of peptides and proteins. Therefore, MS seems to be the method of choice to improve the qualitative and quantitative analysis of peptide and proteins with growth-promoting properties. This review aims to address the opportunities of MS for peptide and protein analysis in veterinary control and sports-doping control with a particular focus on detection of illicit growth promotion. An overview of potential peptide and protein targets, including their amino acid sequence characteristics and current MS-based detection strategies is, therefore, provided. Furthermore, improvements of current and new detection strategies with state-of-the-art MS instrumentation are discussed for qualitative and quantitative approaches.
Collapse
Affiliation(s)
- Irene van den Broek
- RIKILT Wageningen UR, Institute of Food Safety, Akkermaalsbos 2, 6708, WB, Wageningen, The Netherlands
- Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center (LUMC), Albinusdreef 2, 2333, ZA, Leiden, The Netherlands
| | - Marco Blokland
- RIKILT Wageningen UR, Institute of Food Safety, Akkermaalsbos 2, 6708, WB, Wageningen, The Netherlands
| | - Merel A Nessen
- RIKILT Wageningen UR, Institute of Food Safety, Akkermaalsbos 2, 6708, WB, Wageningen, The Netherlands
| | - Saskia Sterk
- RIKILT Wageningen UR, Institute of Food Safety, Akkermaalsbos 2, 6708, WB, Wageningen, The Netherlands
| |
Collapse
|
8
|
Ketha H, Singh RJ. Clinical assays for quantitation of insulin-like-growth-factor-1 (IGF1). Methods 2015; 81:93-8. [PMID: 25937392 DOI: 10.1016/j.ymeth.2015.04.029] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2015] [Revised: 04/20/2015] [Accepted: 04/23/2015] [Indexed: 01/13/2023] Open
Abstract
Insulin-like growth factor 1 (IGF1), a 70 amino acid peptide hormone is the principal mediator of effects of growth hormone (GH). Since GH secretion is pulsatile in nature and is affected by many factors including sleep, feeding and exercise it is not a reliable marker for diagnosis of GH related disorders. On the other hand, IGF1 levels does not undergo short-term fluctuations in the manner that GH does making it the preferred IGF1 biomarker for the diagnosis of growth related disorders. There are several immunoassays available for IGF1 determination. Since majority (>90%) of IGF1 circulates as a ternary complex bound to its principal carrier/binding protein, IGF binding protein 3 (IGFBP3) and acid labile subunit (ALS), the assay methodology used to quantitate IGF1 has to dissociate IGF1 from IGFBPs prior to quantitation. IGFBPs are known to be a source of interference in immunoassays and many techniques have been employed to circumvent this issue. Immunoassays rely on antibody specificity towards IGF1 and differential cross reactivity towards IGFBPs. Mass spectrometry (MS) has also been employed for quantitation of IGF1. Liquid chromatography tandem mass spectrometry (LC-MS/MS) assays for IGF1 rely on generating tryptic peptides followed by selective reaction monitoring (SRM) while LC high resolution accurate-mass mass spectrometry (LC-HRAMS) approaches for intact IGF1 rely on mass accuracy for reliable, robust and accurate quantitation. This review article will focus on the clinical assays available and the clinical utility of quantitative assessment of IGF1. IGF1 quantitation using diverse assay platforms including immunoassay, LC-MS/MS and LC-HRAMS are discussed in detail.
Collapse
Affiliation(s)
- Hemamalini Ketha
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, United States
| | - Ravinder J Singh
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, United States.
| |
Collapse
|
9
|
Oran PE, Trenchevska O, Nedelkov D, Borges CR, Schaab MR, Rehder DS, Jarvis JW, Sherma ND, Shen L, Krastins B, Schwenke DC, Reaven PD, Nelson RW. Parallel workflow for high-throughput (>1,000 samples/day) quantitative analysis of human insulin-like growth factor 1 using mass spectrometric immunoassay. PLoS One 2014; 9:e92801. [PMID: 24664114 PMCID: PMC3963945 DOI: 10.1371/journal.pone.0092801] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2013] [Accepted: 02/26/2014] [Indexed: 12/11/2022] Open
Abstract
Insulin-like growth factor 1 (IGF1) is an important biomarker for the management of growth hormone disorders. Recently there has been rising interest in deploying mass spectrometric (MS) methods of detection for measuring IGF1. However, widespread clinical adoption of any MS-based IGF1 assay will require increased throughput and speed to justify the costs of analyses, and robust industrial platforms that are reproducible across laboratories. Presented here is an MS-based quantitative IGF1 assay with performance rating of >1,000 samples/day, and a capability of quantifying IGF1 point mutations and posttranslational modifications. The throughput of the IGF1 mass spectrometric immunoassay (MSIA) benefited from a simplified sample preparation step, IGF1 immunocapture in a tip format, and high-throughput MALDI-TOF MS analysis. The Limit of Detection and Limit of Quantification of the resulting assay were 1.5 μg/L and 5 μg/L, respectively, with intra- and inter-assay precision CVs of less than 10%, and good linearity and recovery characteristics. The IGF1 MSIA was benchmarked against commercially available IGF1 ELISA via Bland-Altman method comparison test, resulting in a slight positive bias of 16%. The IGF1 MSIA was employed in an optimized parallel workflow utilizing two pipetting robots and MALDI-TOF-MS instruments synced into one-hour phases of sample preparation, extraction and MSIA pipette tip elution, MS data collection, and data processing. Using this workflow, high-throughput IGF1 quantification of 1,054 human samples was achieved in approximately 9 hours. This rate of assaying is a significant improvement over existing MS-based IGF1 assays, and is on par with that of the enzyme-based immunoassays. Furthermore, a mutation was detected in ∼1% of the samples (SNP: rs17884626, creating an A→T substitution at position 67 of the IGF1), demonstrating the capability of IGF1 MSIA to detect point mutations and posttranslational modifications.
Collapse
Affiliation(s)
- Paul E Oran
- Molecular Biomarkers Laboratory, Biodesign Institute, Arizona State University, Tempe, Arizona, United States of America
| | - Olgica Trenchevska
- Molecular Biomarkers Laboratory, Biodesign Institute, Arizona State University, Tempe, Arizona, United States of America
| | - Dobrin Nedelkov
- Molecular Biomarkers Laboratory, Biodesign Institute, Arizona State University, Tempe, Arizona, United States of America
| | - Chad R Borges
- Molecular Biomarkers Laboratory, Biodesign Institute, Arizona State University, Tempe, Arizona, United States of America
| | - Matthew R Schaab
- Molecular Biomarkers Laboratory, Biodesign Institute, Arizona State University, Tempe, Arizona, United States of America
| | - Douglas S Rehder
- Molecular Biomarkers Laboratory, Biodesign Institute, Arizona State University, Tempe, Arizona, United States of America
| | - Jason W Jarvis
- Molecular Biomarkers Laboratory, Biodesign Institute, Arizona State University, Tempe, Arizona, United States of America
| | - Nisha D Sherma
- Molecular Biomarkers Laboratory, Biodesign Institute, Arizona State University, Tempe, Arizona, United States of America
| | - Luhui Shen
- Center for Innovations in Medicine, Biodesign Institute, Arizona State University, Tempe, Arizona, United States of America
| | - Bryan Krastins
- Thermo Fisher Scientific, The Biomarkers Research Initiatives in Mass Spectrometry Center, Cambridge, Massachusetts, United States of America
| | - Dawn C Schwenke
- Phoenix VA Health Care System, Phoenix, Arizona, United States of America; College of Nursing & Health Innovation, Arizona State University, Phoenix, Arizona, United States of America
| | - Peter D Reaven
- Phoenix VA Health Care System, Phoenix, Arizona, United States of America
| | - Randall W Nelson
- Molecular Biomarkers Laboratory, Biodesign Institute, Arizona State University, Tempe, Arizona, United States of America
| |
Collapse
|
10
|
Dervilly-Pinel G, Prévost S, Monteau F, Le Bizec B. Analytical strategies to detect use of recombinant bovine somatotropin in food-producing animals. Trends Analyt Chem 2014. [DOI: 10.1016/j.trac.2013.08.006] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
11
|
Targeted selected reaction monitoring mass spectrometric immunoassay for insulin-like growth factor 1. PLoS One 2013; 8:e81125. [PMID: 24278387 PMCID: PMC3836743 DOI: 10.1371/journal.pone.0081125] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2013] [Accepted: 10/09/2013] [Indexed: 11/30/2022] Open
Abstract
Insulin-like growth factor 1 (IGF1) is an important biomarker of human growth disorders that is routinely analyzed in clinical laboratories. Mass spectrometry-based workflows offer a viable alternative to standard IGF1 immunoassays, which utilize various pre-analytical preparation strategies. In this work we developed an assay that incorporates a novel sample preparation method for dissociating IGF1 from its binding proteins. The workflow also includes an immunoaffinity step using antibody-derivatized pipette tips, followed by elution, trypsin digestion, and LC-MS/MS separation and detection of the signature peptides in a selected reaction monitoring (SRM) mode. The resulting quantitative mass spectrometric immunoassay (MSIA) exhibited good linearity in the range of 1 to 1,500 ng/mL IGF1, intra- and inter-assay precision with CVs of less than 10%, and lowest limits of detection of 1 ng/mL. The linearity and recovery characteristics of the assay were also established, and the new method compared to a commercially available immunoassay using a large cohort of human serum samples. The IGF1 SRM MSIA is well suited for use in clinical laboratories.
Collapse
|
12
|
Kwok WH, Ho ENM, Lau MY, Leung GNW, Wong ASY, Wan TSM. Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography–mass spectrometry. Anal Bioanal Chem 2013; 405:2595-606. [DOI: 10.1007/s00216-012-6697-9] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2012] [Revised: 12/11/2012] [Accepted: 12/22/2012] [Indexed: 02/06/2023]
|
13
|
Thevis M, Thomas A, Schänzer W. Doping control analysis of selected peptide hormones using LC–MS(/MS). Forensic Sci Int 2011; 213:35-41. [DOI: 10.1016/j.forsciint.2011.06.015] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2011] [Revised: 06/14/2011] [Accepted: 06/14/2011] [Indexed: 10/18/2022]
|
14
|
Metabolism of anabolic steroids and their relevance to drug detection in horseracing. Bioanalysis 2011; 2:1085-107. [PMID: 21083210 DOI: 10.4155/bio.10.57] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
The fight against doping in sport using analytical chemistry is a mature area with a history of approximately 100 years in horseracing. In common with human sport, anabolic/androgenic steroids (AASs) are an important group of potential doping agents. Particular issues with their detection are extensive metabolism including both phase I and phase II. A number of the common AASs are also endogenous to the equine. A further issue is the large number of synthetic steroids produced as pharmaceutical products or as 'designer' drugs intended to avoid detection or for the human supplement market. An understanding of the metabolism of AASs is vital to the development of effective detection methods for equine sport. The aim of this paper is to review current knowledge of the metabolism of appropriate steroids, the current approaches to their detection in equine sport and future trends that may affect equine dope testing.
Collapse
|
15
|
Abstract
The fight against doping in sport using analytical chemistry is a mature area with a history of approximately 100 years in horse racing and at least 40 years in human sport. Over that period, the techniques used and the breadth of coverage have developed significantly. These improvements in the testing methods have been matched by the increased sophistication of the methods, drugs and therapies available to the cheat and, as a result, testing has been a reactive process constantly adapting to meet new threats. Following the inception of the World Anti-Doping Agency, research into the methods and technologies available for human doping control have received coordinated funding on an international basis. The area of biomarker research has been a major beneficiary of this funding. The aim of this article is to review recent developments in the application of biomarkers to doping control and to assess the impact this could make in the future.
Collapse
|
16
|
Abstract
Two important biomarkers for the identification of growth hormone or IGF-I administration are IGF-I and P-III-P. These substances are determined in plasma or preferably in serum. There are a number of assays on the market for IGF-I but only two for P-III-P. The principles behind these assays and the choice of assays for doping control purposes are discussed. The future possibility of quantification by mass spectrometry is also briefly discussed.
Collapse
Affiliation(s)
- David A Cowan
- Drug Control Centre, Department of Forensic Science and Drug Monitoring, King's College London, London SE1 9NH, United Kingdom.
| | | |
Collapse
|
17
|
Sofianos ZD, Katsila T, Kostomitsopoulos N, Balafas V, Matsoukas J, Tselios T, Tamvakopoulos C. In vivo evaluation and in vitro metabolism of leuprolide in mice--mass spectrometry-based biomarker measurement for efficacy and toxicity. JOURNAL OF MASS SPECTROMETRY : JMS 2008; 43:1381-1392. [PMID: 18438975 DOI: 10.1002/jms.1416] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
The study of pharmacologically active peptides is central for the understanding of cancer and the development of novel therapeutic approaches. In this context, both qualitative and quantitative determination of bioactive peptides in biological fluids/tissues and their effect on endogenous factors (e.g. hormones) are of great importance. A mass spectrometry-based approach was developed and applied towards the measurement of leuprolide, a peptide drug for the treatment of prostate cancer, in mouse plasma. High-pressure liquid chromatography coupled to a hybrid quadrupole linear ion trap (QqLIT) mass spectrometer, a platform that combines the benefits of triple QqLIT instruments, was employed for the study. Using the described methodology, we established that picomolar concentrations of leuprolide could be measured in mouse plasma (limit of quantification of 0.1 ng/ml). In order to optimize pharmacokinetic properties of analogs of leuprolide, a facile in vivo mouse model was developed and leuprolide concentrations were determined in mouse plasma following intraperitoneal administration. In the same animal model, we demonstrated the versatility of the described MS-based approach by the determination of plasma concentrations of testosterone, an established biomarker for the treatment of prostate cancer. Following dosing with leuprolide, circulating testosterone was increased significantly in comparison to vehicle-treated mice. Finally, in vitro metabolism of leuprolide was evaluated by incubation of leuprolide with mouse kidney membranes, followed by identification of major metabolites by MS. Such studies provide the framework for future evaluation of novel leuprolide analogs with potential therapeutic advantages.
Collapse
Affiliation(s)
- Zacharias D Sofianos
- Division of Pharmacology-Pharmacotechnology, Biomedical Research Foundation, Academy of Athens, Athens 11527, Greece
| | | | | | | | | | | | | |
Collapse
|
18
|
Determination of IGF-I in horse plasma by LC electrospray ionisation mass spectrometry. Anal Bioanal Chem 2008; 390:1843-52. [DOI: 10.1007/s00216-008-1889-z] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2007] [Revised: 01/04/2008] [Accepted: 01/17/2008] [Indexed: 11/26/2022]
|
19
|
Bredehöft M, Schänzer W, Thevis M. Quantification of human insulin-like growth factor-1 and qualitative detection of its analogues in plasma using liquid chromatography/electrospray ionisation tandem mass spectrometry. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2008; 22:477-485. [PMID: 18236437 DOI: 10.1002/rcm.3388] [Citation(s) in RCA: 69] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
Human insulin-like growth factor-1 (IGF-1) is a peptide hormone that acts as a mediator of most of the somatotropic effects of growth hormone (GH). Therefore, it is supposed to be a biomarker indicating GH abuse in sports as well as diseases associated with a change in IGF-1 plasma concentration. It can be applied locally by injection to increase total protein and DNA content in tissues such as skeletal muscle--a highly desirable effect in various sports disciplines. In order to improve its growth-promoting properties, the primary structure of IGF-1 has been modified, yielding analogues such as des(1-3)IGF-1 and LONGR3IGF-1, which show a considerably reduced affinity to the respective binding proteins in plasma and, thus, an increased bioavailability at target tissues. Due to their capability to enhance performance, IGF-1 and its analogues belong to the prohibited list of the World Anti-Doping Agency. Hence, it was necessary to develop a reliable assay for the quantification of human IGF-1 as well as the detection of its derivatives. Immunoaffinity isolation and purification from 60 microL of plasma followed by liquid chromatography/electrospray ionisation tandem mass spectrometry enabled the unequivocal determination of all target analytes. Diagnostic product ions were characterised utilising an Orbitrap mass spectrometer with high resolution/high accuracy properties and employed for triple quadrupole MS/MS analysis. The described assay provided lower limits of detection (LLODs) between 20 and 50 ng/mL, recovery rates between 34-43% and a precision <15% at the LLOD as well as higher concentration levels. In order to prove the applicability of the developed assay, human plasma samples were analysed and the results were compared with the values obtained from a commercially available immunoradiometric assay (IRMA). Four of six samples resulted in concentration ratios with good correlation between both assays, whereas the absolute concentrations were lower for the presented procedure.
Collapse
Affiliation(s)
- Michael Bredehöft
- Center for Preventive Doping Research - Institute of Biochemistry, German Sport University Cologne, Carl-Diem-Weg 6, 50933 Cologne, Germany.
| | | | | |
Collapse
|
20
|
Huang Y, Shi R, Zhong X, Wang D, Zhao M, Li Y. Enzyme-linked immunosorbent assays for insulin-like growth factor-I using six-histidine tag fused proteins. Anal Chim Acta 2007; 596:116-23. [PMID: 17616248 DOI: 10.1016/j.aca.2007.06.003] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2006] [Revised: 03/28/2007] [Accepted: 06/04/2007] [Indexed: 11/22/2022]
Abstract
The fusion proteins of insulin-like growth factor-I (IGF-I) and six-histidine tag (IGF-I-6H, 6H-IGF-I-6H) were cloned, expressed, purified and renatured, with their immunoreaction properties and biological activities intact. The binding kinetics between these fusion proteins and anti-IGF-I antibody or anti-6H antibody were studied using surface plasmon resonance (SPR). Two enzyme-linked immunosorbent assay (ELISA) modes, which proved feasible in the measurement of human serum samples, were used to detect IGF-I with the help of the six-histidine tagged proteins. Furthermore, combining the production technique of the six-histidine tagged fusion protein with the competitive sandwich ELISA mode, using an enzyme labeled anti-6H antibody as a tracer, can be a universal immunochemical method to quantitate other polypeptides or proteins.
Collapse
Affiliation(s)
- Yong Huang
- College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China
| | | | | | | | | | | |
Collapse
|
21
|
Tamvakopoulos C. Mass spectrometry for the quantification of bioactive peptides in biological fluids. MASS SPECTROMETRY REVIEWS 2007; 26:389-402. [PMID: 17160998 DOI: 10.1002/mas.20120] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
The study of pharmacologically active peptides is central to the understanding of disease and development of novel therapies. It would be advantageous to monitor the fate of bioactive peptides in biological fluids and tissues following their in vivo administration (exogenous administration) or the modulation of endogenous factors (e.g., peptide hormones) affected by the administration of a pharmacological agent. Measurement of administered compounds (small molecules) in plasma is a mature field. However, measurement of pharmacologically active peptides presents particular problems for quantitative mass spectrometry, including challenges from selectivity and sensitivity perspectives. Current approaches towards peptide quantification in biological fluids include immunoassays and mass spectrometric techniques. Immunoassays, although sensitive, lack the necessary selectivity for distinction between peptide and metabolites. Modified molecules induced by metabolic transformations (e.g., N- or C-terminal truncation of the peptide) might not be differentiated by the antibody used in the assay, leading to cross-reactivity. However, although it is generally accepted that mass spectrometry is an ideal technique for the quantification of trace levels of analytes in biological fluids, immunological techniques are still characterized by better limits of peptide detection. In this review article, novel mass spectrometric approaches and strategies on peptide quantification will be described. The current capabilities and prospects for advances in this critical area of research will be examined.
Collapse
Affiliation(s)
- Constantin Tamvakopoulos
- Foundation for Biomedical Research of the Academy of Athens (IIBEAA), Laboratory of Pharmacology-Pharmacotechnology, Athens, Greece 11527.
| |
Collapse
|
22
|
de Graaf‐Roelfsema E, Keizer H, van Breda E, Wijnberg I, van der Kolk J. Hormonal responses to acute exercise, training and overtraining a review with emphasis on the horse. Vet Q 2007; 29:82-101. [DOI: 10.1080/01652176.2007.9695232] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022] Open
|
23
|
Nelson RW, Nedelkov D, Tubbs KA, Kiernan UA. Quantitative Mass Spectrometric Immunoassay of Insulin Like Growth Factor 1. J Proteome Res 2004; 3:851-5. [PMID: 15359740 DOI: 10.1021/pr0499388] [Citation(s) in RCA: 62] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Reported in this work are the development of mass spectrometric immunoassay (MSIA) devices and methods for the qualitative analysis of IGF-1 and -2, and the rigorous quantification of IGF-1 from human plasma. A method involving addition of SDS in moderate concentration to unfractionated plasma for disrupting IGF/IGFBP complexes was initially developed. The method is suitable for the direct extraction of the IGFs and subsequent mass spectrometric analysis. Rat plasma, containing IGF-1 that is mass shifted from human IGF-1, was used as an internal reference standard (IRS) for the quantification of IGF-1 directly from human plasma. A standard curve with linear dynamic range of at least 2 orders of magnitude was constructed from serially diluted IGF-1 standards containing equal amounts of rat plasma. Using the standard curve, IGF-1 levels in plasma samples from eight individuals were determined. The limit of detection for the IGF-1 MSIA was also evaluated and established to be approximately 15 pM. The assay is rapid and can be performed in parallel via high-throughput robotics processing. Furthermore, the mass spectrometry aspect of the developed IGF-1 immunoassay offers a new dimension in the ongoing study of IGF-1 and related diseases.
Collapse
|
24
|
Pinel G, André F, Le Bizec B. Discrimination of recombinant and pituitary-derived bovine and porcine growth hormones by peptide mass mapping. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 2004; 52:407-414. [PMID: 14759125 DOI: 10.1021/jf030536e] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
Somatotropins, which are used in cattle for growth and lactating performances, are difficult to reliably detect because no direct method exists. Reversed-phase high-performance liquid chromatography (RP-HLC) coupled to electrospray ionization quadrupole mass spectrometry (ESI/MS) has been developed to separate and characterize the N-terminal peptides resulting from tryptic cleavage of natural and recombinant growth hormones from different species (bovine, porcine, and human) and suppliers. Conditions for tryptic digestion were optimized. This technique was found to be optimal to cleave efficiently the N-terminal peptide of the proteins without releasing too much noise from the matrix. Characterization of the peptides through ESI(+)-MS allowed natural and recombinant growth hormones from bovine and porcine species with N-terminal amino acid sequences differing from one amino acid residue to be discriminated. However, the studied human growth hormones had similar primary sequences that did not permit any discrimination between recombinant and natural forms, thus confirming the known identity of these hormones. Protein digestions with pepsin and chymotrypsin were also compared but were not conclusive due to the too small N-terminal peptides released after proteolysis.
Collapse
Affiliation(s)
- Gaud Pinel
- LABERCA, Ecole Nationale Vétérinaire de Nantes, Route de Gachet, B.P. 50707, 44307 Nantes Cedex 3, France.
| | | | | |
Collapse
|
25
|
Delinsky DC, Hill KT, White CA, Bartlett MG. Quantitation of the large polypeptide glucagon by protein precipitation and LC/MS. Biomed Chromatogr 2004; 18:700-5. [PMID: 15386587 DOI: 10.1002/bmc.380] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
We present a method for the quantitation of glucagon from rat plasma by protein precipitation and LC/MS. No internal standard was used, as a labeled standard was not available and similar peptides did not show comparable extraction characteristics to glucagon. The LC system included a Keystone C18, 300 A pore size column; a linear gradient was used with a mobile phase consisting of water and acetonitrile, each with 0.2% acetic acid and 0.02% trifluoroacetic acid. Glucagon was detected with the mass spectrometer in positive ion mode monitoring the 4+ charge state at m/z 871.7. The method had an approximated limit of detection of 1 ng/mL. The lower limit of quantitation (LLOQ) was 25 ng/mL (7.2 fmol/mL), which could be reduced with an appropriate internal standard. External calibration was used and calibration curves were found to be linear over the range from 25 to 1000 ng/mL (7.2 to 290 fmol/mL). The method showed a high degree of precision and accuracy both within and between runs at four validation points, including the LLOQ.
Collapse
Affiliation(s)
- David C Delinsky
- Department of Pharmaceutical and Biomedical Sciences, The University of Georgia, Athens, GA 30602-2352, USA
| | | | | | | |
Collapse
|
26
|
Current literature in mass spectrometry. JOURNAL OF MASS SPECTROMETRY : JMS 2001; 36:1076-1082. [PMID: 11599087 DOI: 10.1002/jms.96] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
|